Synovial Tissue as a Biomarker in the Management of Pigmented Villonodular Synovitis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNantes University Hospital

About this trial

Pigmented villonodular synovitis (PVNS) is a rare joint disease caused by the proliferation of synovial tissue, leading to significant pain and joint destruction. It typically begins between the ages of 30 and 50 and significantly affects patients' functionality. The proliferation is due to somatic mutations in some fibroblastic cells within the tissue, which triggers a massive recruitment of inflammatory cells. The condition is considered a benign tumor of the synovial membrane with a major inflammatory component. Diagnosing PVNS requires synovial tissue analysis, obtained either through surgical excision or guided needle biopsy. This biopsy technique, done as an outpatient procedure, is well tolerated and helps confirm the diagnosis before treatment. Our goal is to better understand this disease and determine if the analysis of synovial tissue could serve as a useful biomarker for patient management in the context of personalized medicine.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient >18 years

Diagnosis of localized or diffuse villonodular synovitis

Referred for therapeutic management

Affiliated with or benefiting from a social security scheme

Disqualifiers

Pregnant women

Nursing mothers

Protected patients: patients under guardianship or curatorship, safeguard of justice

Patients deprived of liberty

Trial design

Design model

Single group

Treatments tested in this trial

  • synovial biopsy

    Procedure/Surgery

    Synovial samples are taken either : * immediately after surgery * during an ultrasound-guided synovial biopsy

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: Synovial samplingExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

number of samples

Time frame
1 day

Secondary outcomes

1

Tissue quality

assessed using Krenn's histological score

Time frame
1 month
2

number of adverse events

Time frame
1 year
3

Patient acceptability

using a visual analogue scale

Time frame
1 day
4

Cluster analysis of results from high-throughput experiments

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.